• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Overcoming resistance against HER2-targeting agents in fifth-line therapy: is there still a place for bevacizumab in HER2+ breast cancer?

作者信息

Huemer Florian, Gampenrieder Simon Peter, Schlattau Alexander, Greil Richard

机构信息

Third Medical Department with Hematology, Medical Oncology, Hemostaseology, Infectious Diseases and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute with Laboratory of Immunological and Molecular Cancer Research and Center for Clinical Cancer and Immunology Trials, Paracelsus Medical University Salzburg, Salzburg, Austria.

Department of Radiology, Paracelsus Medical University Salzburg, Salzburg, Austria.

出版信息

Clin Breast Cancer. 2014 Feb;14(1):e17-20. doi: 10.1016/j.clbc.2013.09.009. Epub 2013 Sep 28.

DOI:10.1016/j.clbc.2013.09.009
PMID:24246725
Abstract
摘要

相似文献

1
Overcoming resistance against HER2-targeting agents in fifth-line therapy: is there still a place for bevacizumab in HER2+ breast cancer?克服HER2靶向药物在五线治疗中的耐药性：贝伐单抗在HER2阳性乳腺癌治疗中仍有一席之地吗？
Clin Breast Cancer. 2014 Feb;14(1):e17-20. doi: 10.1016/j.clbc.2013.09.009. Epub 2013 Sep 28.
2
Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts.延缓或治疗人乳腺癌异种移植瘤体内获得性曲妥珠单抗耐药的策略。
Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):904-16. doi: 10.1158/1078-0432.CCR-05-1109.
3
AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.AVEREL：一项随机 III 期临床试验，评估贝伐珠单抗联合多西他赛和曲妥珠单抗作为 HER2 阳性局部复发性/转移性乳腺癌的一线治疗。
J Clin Oncol. 2013 May 10;31(14):1719-25. doi: 10.1200/JCO.2012.44.7912. Epub 2013 Apr 8.
4
Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors.曲妥珠单抗和酪氨酸激酶抑制剂治疗转移性乳腺癌的疗效。
Breast. 2013 Feb;22(1):1-12. doi: 10.1016/j.breast.2012.09.008. Epub 2012 Oct 16.
5
[Mechanisms of resistance to molecular targeted therapies in breast cancer: update and future].[乳腺癌分子靶向治疗的耐药机制：更新与展望]
Bull Cancer. 2010 Mar;97(3):385-95. doi: 10.1684/bdc.2010.1051.
6
[DCIS and HER2/neu].[导管原位癌与人类表皮生长因子受体2/神经（HER2/neu）]
Onkologie. 2002 Dec;25 Suppl 5:11-2; discussion 13.
7
Bevacizumab for the first-line treatment of human epidermal growth factor receptor 2-negative advanced breast cancer.贝伐珠单抗用于人表皮生长因子受体 2 阴性的晚期乳腺癌的一线治疗。
Curr Opin Oncol. 2011 Apr;23 Suppl:S3-9. doi: 10.1097/01.cco.0000397417.75245.9c.
8
[Anti-angiogenic therapy in breast cancer].[乳腺癌的抗血管生成治疗]
Gan To Kagaku Ryoho. 2014 Feb;41(2):153-6.
9
Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.针对 HER2 靶向治疗耐药的策略演进：针对 PI3K/Akt/mTOR 通路。
Clin Breast Cancer. 2010 Nov;10 Suppl 3:S72-8. doi: 10.3816/CBC.2010.s.015.
10
Blockade of the HER family of receptors in the treatment of HER2-positive metastatic breast cancer.阻断 HER 家族受体在治疗 HER2 阳性转移性乳腺癌中的作用。
Clin Breast Cancer. 2012 Feb;12(1):19-29. doi: 10.1016/j.clbc.2011.07.001. Epub 2011 Sep 8.

引用本文的文献

1
A case report of the sustained and rapid response of bevacizumab in a TP53-positive breast cancer and liver metastatic patient through personalized medicine.一例通过精准医疗使用贝伐单抗治疗TP53阳性乳腺癌伴肝转移患者获得持续快速缓解的病例报告。
Front Oncol. 2022 Sep 2;12:940678. doi: 10.3389/fonc.2022.940678. eCollection 2022.
2
Squalamine blocks tumor-associated angiogenesis and growth of human breast cancer cells with or without HER-2/neu overexpression.鲨肝醇抑制肿瘤相关血管生成和 HER-2/neu 过表达或不表达的人乳腺癌细胞的生长。
Cancer Lett. 2019 May 1;449:66-75. doi: 10.1016/j.canlet.2019.02.009. Epub 2019 Feb 13.